Page 426 - An Evidence Review of Active Surveillance in Men With Localized Prostate Cancer

Appendix Table C3.2. KQ3 multivariable analyses (continued)
Author Factors Data source Duration Analyzed Population WW/AS Methods Results as described in paper
yr sample characteristics definitions
PMI
Roberts 180 Clinical, SEER- 2004- 8323 Men ≥75 with No RP, RT, Unconditional 1. Age, OR 0.92 (CI 0.91, 0.94)
2011 geographic Medicare 2005 localized or ADT multivariate 2. Black vs. white, OR 0.57 (CI
21396507 disease, logistic 0.47, 0.68)
excluded HMO, regression 3. Other than black vs. white, OR
dx from predicts 1.34 (CI 1.07, 1.66)
autopsy or active 4. Married vs. unmarried, OR 1.37
death therapy vs. (CI 1.19, 1.58)
certificates, WW 5. Unknown status vs. unmarried,
unknown OR 0.73 (0.61, 0.89)
poverty rate, 6. NE vs. CA and SJ, OR 1.74 (CI
Gleason score, 1.44, 2.09)
PSA, or tumor 7. North Central vs. CA and SJ,
stage OR 1.61 (CI 1.30, 1.99)
8. Other West vs. CA and SJ, OR
1.24 (CI 1.01, 1.53)
9. PSA 10-20 vs. >20, OR 1.21 (CI
1.00, 1.47)
10. Gleason 5-6 vs. 7-10, OR 0.40
(CI 0.36, 0.45)
NS: poverty line, rural vs. urban,
South, LA and SF, tumor stage,
comorbidity
Shavers 166 Clinical, SEER- 1994- 24,974 Black, Hispanic No RP, RT, Binomial 1. Race/ethnic group,
2004 social, Medicare 1996 or White men or ADT logistic - Black vs. White, OR=1.3 (CI
15009794 delivery with prostate within 6 mo regression 1.1, 1.4)
system cancer, ≥65 yr, of dx predicts WW - Hispanic vs. White, OR=1.2 (CI
with continuous as initial 1.03, 1.4)
Medicare Part therapy vs. 2. Stage, SEER historical stage,
A & B coverage all other - in situ vs. local (1994), OR=8.8
for ≥1 yr prior treatments (CI 3.5, 21.7)
to dx - regional vs. local (1994),
OR=0.4 (CI 0.3, 0.4)
- distant vs. local (1994), OR=0.2
(CI 0.1, 0.2)
- local + regional (1995 to 1996)
vs. local (1994), OR=0.9 (CI 0.8,
0.98)
- unstaged/unknown, vs. local
(1994), OR=1.2 (CI 1.1, 1.3)

C-131